Funded Startups in Hayward
Hayward’s most recent funding signals a steep size spread: Eikon Therapeutics (Series D) raised $351M on 2025-02-26, which dwarfs the next-largest disclose…
Hayward’s most recent funding signals a steep size spread: Eikon Therapeutics (Series D) raised $351M on 2025-02-26, which dwarfs the next-largest disclosed rounds at $150M (Arcus Biosciences, 2025-02-18) and $81M (Blue Current, 2025-10-11). The table also shows a tight clustering in early 2025, with multiple biotech and healthcare-linked rounds spanning 2025-02-18 to 2025-02-26, alongside later activity in 2025-07-10 (Aqtual, $31M) and 2025-10-11 (Blue Current, $81M). Sector and stage mix skew heavily toward biotechnology and “Series Unknown”: 9 of 25 entries are Biotechnology, while 9 of 25 are explicitly labeled Series Unknown and 2 of 25 are undisclosed. Temporally, rounds run from 2021-08-01 (Renovai, $3M) through 2025-10-11 (Blue Current), and the most recent row is the only Consumer Electronics entry at a large disclosed amount ($81M).
Most recent rounds
25 shownRelated listings
Frequently asked
What size outliers appear in Hayward’s most recent rounds, and how extreme are they versus the rest of the disclosed amounts?
Eikon Therapeutics’ $351M on 2025-02-26 is the clear size outlier in the disclosed set. The next-largest disclosed rounds are Arcus Biosciences at $150M (2025-02-18) and then Blue Current at $81M (2025-10-11), meaning the $351M round sits well above the rest rather than in the same range.
Are biotech rounds concentrated in a narrow window, or are they spread across multiple years in this Hayward list?
Biotechnology shows a notable early-2025 cluster: Arcus Biosciences ($150M, 2025-02-18) and Eikon Therapeutics ($351M, 2025-02-26) land within eight days. Additional biotech activity appears across 2022–2024 (for example CymaBay Therapeutics $85M on 2023-01-24 and Moximed $61M on 2024-08-13), so it is not limited to a single year.
How concentrated is the round outcome classification (Series Unknown vs disclosed) in this city list?
Nine of the 25 entries are tagged “Series Unknown” (for example Aqtual is Series B, but Blue Current is Series Unknown on 2025-10-11), and two entries are “undisclosed” (Endiatx on 2024-12-01 and YO-KAI EXPRESS on 2022-09-01). That means a little under half of the rows do not provide a specific disclosed stage label, which can complicate stage-based comparisons.
Which sectors are over-represented relative to the rest of the 25 rows in Hayward?
Biotechnology appears 9 times, the only sector reaching 3+ entries (for example Eikon Therapeutics, Arcus Biosciences, Moximed, Spotlight Therapeutics). Consumer Electronics appears 3 times (Blue Current 2025-10-11 $81M; Halio 2023-11-16 $70M; HOMMA 2021-10-15 $6M), while other sectors (AI, Health Care, Financial Services, etc.) show up fewer times.
What does the temporal edge look like for this list—what are the newest and oldest rounds shown?
The newest dated round in the 25-row slice is Blue Current on 2025-10-11 with a disclosed amount of $81M. The oldest dated entry is Renovai on 2021-08-01 with $3M, so the displayed rounds span about four years, with several high-value biotech rounds appearing in early 2025.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.